Krystal Biotech to join S&P MidCap 400 as merger activity drives index changes

Seeking Alpha··Read original
2▲2 ▼0Impact / 5
Summary · why it matters

S&P Dow Jones Indices announced that Krystal Biotech will join the S&P MidCap 400, replacing Taylor Morrison Home before trading opens on July 24. The change follows Berkshire Hathaway's planned acquisition of Taylor Morrison Home, which is expected to close on or around that date. Tutor Perini will replace Krystal Biotech in the S&P SmallCap 600 on the same day. Separately, V2X will replace Avanos Medical in the S&P SmallCap 600 on July 27 after American Industrial Partners' acquisition of Avanos Medical closes.

Impact on assets 7

Biotech & Genomic Medicine▲ · 1 stocks
Krystal Biotech Inc
KRYS
▲ PositiveCapitalrelevance

Krystal Biotech will join the S&P MidCap 400, which typically leads to increased demand from index funds.

Industrials▲ · 1 stocks
Tutor Perini Corporation
TPC
▲ PositiveCapitalrelevance

Tutor Perini will replace Krystal Biotech in the S&P SmallCap 600, which typically leads to increased demand from index funds.

Health Care▲ · 1 stocks
Energy Transition & Power Demand▲ · 1 stocks
Cloud & Digital Infrastructure▲ · 1 stocks
Consumer Discretionary▲ · 1 stocks
Defense & Geopolitical Fragmentation▲ · 1 stocks

Off-coverage companies 1

American Industrial PartnersPrivate± Mixed
relevance

© 2026 MarketIVNews